87 phenotypes from 7 alleles in 6 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Nfkbiatm1.1Kbp/Nfkbiatm1.1Kbp involves: 129P2/OlaHsd * C57BL/6	abnormal erythropoiesis	J:97945
	abnormal granulocyte morphology	J:97945
	increased bone marrow cell number	J:97945
	increased granulocyte number	J:97945
	postnatal growth retardation	J:97945
	postnatal lethality, complete penetrance	J:97945
Nfkbiatm1.1Pjc/Nfkbiatm1.1Pjc involves: C57BL/6	abnormal circulating cytokine level	J:163686
	abnormal T cell activation	J:163686
	abnormal T cell number	J:163686
	autoimmune response	J:163686
	chronic inflammation	J:163686
	decreased CD4-positive, alpha-beta T cell number	J:163686
	decreased CD8-positive, alpha-beta T cell number	J:163686
	increased activated T cell number	J:163686
	increased anti-insulin autoantibody level	J:163686
	increased anti-nuclear antigen antibody level	J:163686
	increased circulating interleukin-1 alpha level	J:163686
	increased circulating interleukin-17 level	J:163686
	increased circulating tumor necrosis factor level	J:163686
	increased double-positive T cell number	J:163686
	increased memory T cell number	J:163686
	increased susceptibility to bacterial infection induced morbidity/mortality	J:163686
	increased T cell apoptosis	J:163686
	increased T cell proliferation	J:163686
	increased thymocyte number	J:163686
	premature death	J:163686
Nfkbiatm1.1Smiy/Nfkbia+ B6.129-Nfkbiatm1.1Smiy	decreased B cell number	J:168977
	decreased follicular B cell number	J:168977
	decreased marginal zone B cell number	J:168977
	decreased transitional stage T2 B cell number	J:168977
	increased pro-B cell number	J:168977
	small Peyer's patches	J:168977
Nfkbiatm1.1Smiy/Nfkbiatm1.1Smiy B6.129-Nfkbiatm1.1Smiy	abnormal B cell differentiation	J:168977
	abnormal marginal zone B cell morphology	J:168977
	decreased B cell number	J:168977
	decreased B cell proliferation	J:168977
	decreased B-2 B cell number	J:168977
	decreased CD4-positive, alpha-beta memory T cell number	J:168977
	decreased follicular B cell number	J:168977
	decreased IgA level	J:168977
	decreased IgG1 level	J:168977
	decreased IgG2b level	J:168977
	decreased marginal zone B cell number	J:168977
	decreased mature B cell number	J:168977
	decreased Peyer's patch number	J:168977
	decreased regulatory T cell number	J:168977
	decreased transitional stage T2 B cell number	J:168977
	increased activation-induced B cell apoptosis	J:168977
	increased immature B cell number	J:168977
	increased pre-B cell number	J:168977
	increased pro-B cell number	J:168977
	small Peyer's patches	J:168977
Nfkbiatm1Bal/Nfkbiatm1Bal involves: 129S4/SvJae * C57BL/6J	abnormal epidermis stratum basale morphology	J:30058
	abnormal granulocyte differentiation	J:30058
	abnormal skin condition	J:30058
	decreased body size	J:30058
	decreased double-positive T cell number	J:30058
	flaky skin	J:30058
	increased leukocyte cell number	J:30058
	postnatal lethality, complete penetrance	J:30058
	scaly skin	J:30058
	spleen atrophy	J:30058
	thymus atrophy	J:30058
Nfkbiatm1Fey/Nfkbiatm1Fey involves: 129S6/SvEvTac * C57BL/6	abnormal B cell differentiation	J:110817
	abnormal cell differentiation	J:110817
	abnormal cell physiology	J:110817
	abnormal humoral immune response	J:110817
	absent spleen germinal center	J:110817
	anemia	J:110817
	decreased body size	J:110817
	decreased body weight	J:110817
	decreased double-negative T cell number	J:110817
	decreased T cell proliferation	J:110817
	decreased thymocyte number	J:110817
	dry skin	J:110817
	increased B cell proliferation	J:110817
	increased IgA level	J:110817
	increased IgE level	J:110817
	increased IgG level	J:110817
	increased single-positive T cell number	J:110817
	postnatal lethality, complete penetrance	J:110817
	reddish skin	J:110817
	scaly skin	J:110817
	small spleen	J:110817
	thymus atrophy	J:110817
Nfkbiatm1Kbp/Nfkbiatm1Kbp Lyz2tm1(cre)Ifo/Lyz2+ involves: 129P2/OlaHsd * C57BL/6	normal hematopoietic system phenotype	J:97945
Nfkbiatm1Stw/Nfkbiatm1Stw involves: 129S1/Sv	abnormal epidermis stratum corneum morphology	J:32527
	abnormal epidermis stratum granulosum morphology	J:32527
	abnormal erythropoiesis	J:32527
	abnormal keratinocyte morphology	J:32527
	abnormal macrophage physiology	J:32527
	abnormal myelopoiesis	J:32527
	abnormal tumor necrosis factor level	J:32527
	acanthosis	J:32527
	decreased body weight	J:32527
	dermatitis	J:32527
	dry skin	J:32527
	extramedullary hematopoiesis	J:32527
	flaky skin	J:32527
	hyperkeratosis	J:32527
	increased macrophage cell number	J:32527
	increased monocyte cell number	J:32527
	postnatal growth retardation	J:32527
	postnatal lethality, complete penetrance	J:32527
	spontaneous skin ulceration	J:32527